Have any thoughts about
Seagen Inc?
Write Note

Seagen Inc
Goodwill

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Seagen Inc
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Goodwill CAGR 3Y CAGR 5Y CAGR 10Y
S
Seagen Inc
F:SGT
Goodwill
$274.7m
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Goodwill
$35.3B
CAGR 3-Years
3%
CAGR 5-Years
18%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Goodwill
$8.3B
CAGR 3-Years
0%
CAGR 5-Years
15%
CAGR 10-Years
22%
Amgen Inc
NASDAQ:AMGN
Goodwill
$18.7B
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Goodwill
$1.1B
CAGR 3-Years
3%
CAGR 5-Years
19%
CAGR 10-Years
43%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Seagen Inc
Glance View

Market Cap
39.3B EUR
Industry
Biotechnology
Economic Moat
None

Seagen Inc., nestled in the vibrant Pacific Northwest, has carved out a formidable niche in the biotech arena with its relentless focus on oncology advancements. Born in 1997 as Seattle Genetics, this company has developed a reputation for its pioneering work in antibody-drug conjugates (ADCs). These innovative therapies are designed to deliver potent anti-cancer agents directly to tumor cells, minimizing damage to healthy tissues. Its flagship product, Adcetris, targets various Hodgkin’s lymphomas and has been instrumental in redefining treatment paradigms. This high-caliber development is not just a product of cutting-edge science, but of Seagen's strategic approach to partnerships and collaborations with other pharmaceutical giants, amplifying its research and market reach. Revenue for Seagen doesn't merely stem from its internal product pipeline; it also thrives on strategic alliances and licensing agreements. By engaging in collaborations with leading firms like Pfizer and Takeda, Seagen extends its influence beyond its direct sales, earning substantial sums from milestone payments and royalties as partners bring drugs to market. Furthermore, its business model is deeply entwined with a global vision, where navigating regulatory landscapes across different countries not only expands its market share but also its scientific influence. Seagen’s business strategy is a testament to how innovation in drug delivery mechanisms and thoughtful alliances can coalesce into a formidable presence in the biopharmaceutical industry, fueling both growth and a greater mission in the fight against cancer.

SGT Intrinsic Value
143.78 EUR
Overvaluation 31%
Intrinsic Value
Price
S

See Also

What is Seagen Inc's Goodwill?
Goodwill
274.7m USD

Based on the financial report for Sep 30, 2023, Seagen Inc's Goodwill amounts to 274.7m USD.

What is Seagen Inc's Goodwill growth rate?
Goodwill CAGR 5Y
2%

Over the last year, the Goodwill growth was 0%.

Back to Top